PubMed Health⌕ Search

Biomedical subjects

L Piccinini

Publications and source records attributed to L Piccinini.

At least 55 records · Page 3Linked to original sources
PubMed1980

Autoradiographic studies on lymph node populations from non-Hodgkin B lymphomas.

The authors have investigated the cytokinetic behaviour of 23 cases of non-Hodgkin B cell lymphomas. In all cases diagnosis was established on the basis of histological, cytoimmunological and cytochemical data. The study, carried out with the aid of autoradiographic techniques, indicates that the various histological subclasses are characterized by a different metabolic and kinetic behaviour: the aggressiveness of the malignant lymphoma is closely related to the rate of growth of the lymphomatous cell populations, as assessed by the mitotic index and the labelling index with 3H-thymidine. The study of the synthesis and metabolism of RNA provides not only useful information on the energy requirements necessary for the neoplastic growth, but, when employed in association with immunohistochemical techniques for the detection of intracytoplasmic Ig synthesis, it defines more accurately the functional characteristics and the differentiation potentialities of the neoplastic populations in different cases.

Aged↗
PubMed1977

[Etiopathogenetical, clinical and therapeutic considerations on meningo-encephalic localizations in acute lymphatic leukemias: personal contribution].

The aetiology, pathogenesis, clinical forms and therapeutic attempts carried out in connection with the central nervous system localizations in acute lymphoblastic leukaemia, on the basis of an extensive review of the literature and of personal experience are examined. The particular role which central nervous system leukaemia plays on the subsequent clinical course of the disease is stressed and the efforts made, both prophylactically and therapeutically, in order to decrease the incidence of this complication, which invariably has a deteriorating influence of the progress of the disease are described.

Adolescent↗
PubMedDate not supplied

Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy.

Data on the long-term treatment of myeloma bone disease with bisphosphonates are scanty. In a prospective pilot trial we evaluated the effect of long-term parenteral administration of dichloromethylene bisphosphonate (Clodronate), in addition to standard chemotherapy, in 30 patients with active myeloma bone disease. Patients were treated with a mean of 4 courses (range 2-8) of Clodronate: 300 mg/day i.v. for seven days followed by 100 mg/day i.m. for 10 days, administered at a mean interval of 4 months (range 3-6). The median follow-up was 24 months (range 8-36). Clodronate reduced bone pain rapidly and significantly, and reduced the mean values of the biochemical indices of bone resorption to within normal limits; these effects were maintained throughout the follow-up. In three hypercalcemic episodes serum calcium became normal after 2-5 days of treatment with Clodronate. No toxic or side effects were noticed. The occurrence of skeletal morbidity in patients treated with Clodronate was compared with that observed in the control group of myeloma patients (p less than 0.001) in severe bone pain as well as in the incidence of new osteolytic lesions and pathological fractures (p less than 0.001). Supportive Clodronate therapy contributes significantly in controlling the progression of myeloma bone disease.

Bone Diseases↗
PubMedDate not supplied

Occasional diagnosis of synchronous renal cell carcinoma during staging of other primary tumors.

Synchronous renal cell cancer (RCC) associated with primary neoplasms of other organs or tissues represents a rare diagnostic report during life. Recently, the widespread use of new diagnostic techniques (echography, computed tomography and magnetic resonance imaging) has permitted diagnosis of clinically silent RCC. We report 6 RCC cases occasionally diagnosed during initial staging of a primary cancer of other organs: 1 rhinopharyngeal carcinoma, 1 gastric cancer, 1 Waldenström's disease, 1 non-Hodgkin's lymphoma, 2 breast cancer, RCC was clinically silent in all patients. The diagnostic problems related to a report of a renal mass in patients with neoplastic disease at other sites and the consequent therapeutic implications are discussed.

Aged↗
PubMedDate not supplied

Plasma fibronectin in hemoblastosis.

Fibronectin (FN) is a glycoprotein whose plasma concentrations are reduced in many pathological conditions. In patients with hemoblastosis plasma FN was correlated with some clinical and biological parameters (stage of the disease, hepatosplenomegaly, infections and DIC), in order to assess its value as a tumor marker. The results suggest a poor relationship between FN levels and the course of the disease. However, the behaviour of the protein in relation with treatment was dynamic.

Biomarkers, Tumor↗
PubMedDate not supplied

Urinary neopterin in malignant lymphoma.

Urinary neopterin levels were studied in 96 patients with malignant lymphomas. Twenty-eight had Hodgkin's disease and 68 non-Hodgkin's lymphoma. Neopterin excretion was significantly related to the clinical stage of the disease. Mean neopterin excretion in patients with active disease (634 +/- 527 mumol neopterin/mol creatinine) was significantly higher (p = 0.000) than in patients in complete remission (198 +/- 105 mumol neopterin/mol creatinine). Mean neopterin levels of patients in stage III-IV were higher than for patients in stage I-II. These findings were the same in patients with Hodgkin's disease and those with non-Hodgkin's lymphoma (659 +/- 593-425 +/- 316 mumol neopterin/mol creatinine), regardless of the histological subtype. A significant correlation was found between neopterin excretion, ESR (r = 0.31; p = 0.003) and hemoglobin (r = -0.40; p = 0.000). Longitudinal analysis showed a trend towards a correlation between response to therapy and neopterin excretion. These findings suggest that neopterin may be a useful prognostic marker in non-Hodgkin's lymphoma.

Adult↗
PubMedDate not supplied

Primary gastrointestinal lymphoma: a clinicopathological study of 58 cases.

BACKGROUND: Primary non Hodgkin's lymphoma (NHL) of the gastrointestinal tract (GI) is the most frequent extranodal lymphoma accounting for approximately 40% of all extranodal primary NHL. The role of surgery and other treatment modalities in the management of these patients is still controversial. PATIENTS AND METHODS: We reviewed the records of 68 patients with primary GI-NHL. Ten patients had incomplete records and were excluded from further evaluation. The records of 58 patients were considered, and all were available for analysis and follow-up. RESULTS: The most frequent site of involvement was the stomach (47 patients), followed by ileum (7 patients), large bowel (3 patients) and duodenum (1 patient). Malignant lymphomas of follicular center cell origin represented the most prevalent histologic types, accounting for 58% (34 of 58) of all cases. Stage, evaluated according to the criteria of Musshoff, was Ie in 15 cases, IIe in 16, IIIe in 7, and IV in the remaining 20 cases. The median survival for the entire group of 58 patients was 54 months, with 46% of patients surviving at 5 years. The median survival was 71 months for patients in stage I-II, 60 for patients in stage III, and 25 for patients in stage IV (p = 0.016). Moreover, we found significantly improved survival in patients undergoing surgical tumor resection (p = 0.003). CONCLUSIONS: Even if at the present time the optimal management of primary GI-NHL is difficult to assess, our data suggest that it is prudent to advise resection followed by adjuvant CT in most patients, whereas CT alone should be considered only when surgery cannot be performed.

Adolescent↗